{
  "id": "adv_mhgap#risk_safety_000ffea6",
  "content": "(SSRIs for GAD; SSRIs as first-line treatment and then\nCitalopram indicated minimal efficacy and high risk\nTCAs as second-line treatment for panic disorder)\nof adverse events. However, individual analyses are\nthat are accessible should be favoured, as evidence\n18\n3. Recommendations\ndoes not indicate a statistically significant difference LMICs) may interfere with continuation of treatment.\nbetween the individual antidepressant medicines in y Specific types of antidepressants selected should\nthese classes for anxiety disorders. carefully consider factors such as demographic\ny TCAs are generally less well tolerated than SSRIs characteristics (e.g. higher risks and side-effects\nand also generally considered less safe, due to that may be associated with pregnancy or older\nanticholinergic side-effects, toxicity, psychomotor age), side-effects profiles (e.g. sexual dysfunction,\nand cognitive impairment risks, and lethality risks sleep problems, weight gain) and availability (e.g.\nin cases of acute intoxication or overdose. TCAs are continuous availability, costs).\ntherefore recommended for consideration in cases y Support the person in making a decision between\nwhere SSRIs are not available for adults with panic antidepressants and psychological interventions (if\ndisorder. available), based on providing relevant information\ny TCAs should be avoided in older adults and in (e.g. possible side-effects, costs). Before prescribing",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep",
      "risk_safety",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Risk Safety (SSRIs for GAD; SSRIs as first-line treatment and then\nCitalopram indicated minimal efficacy and high risk\nTCAs as second-line treatment for panic disorder)\nof adverse events. However, individual analyses are\nthat are accessible should be favoured, as evidence\n18\n3. Recommendations\ndoes not indicate a statistically significant difference LMICs) may interfere with continuation of treatment.\nbetween the individual antidepressant medicines in y Specific types of antidepressants selected should\nthese classes for anxiety disorders. carefully consider factors such as demographic\ny TCAs are generally less well tolerated than SSRIs characteristics (e.g. higher risks and side-effects\nand also generally considered less safe, due to that may be associated with pregnancy or older\nanticholinergic side-effects, toxicity, psychomotor age), side-effects profiles (e.g. sexual dysfunction,\nand cognitive impairment risks, and lethality risks sleep problems, weight gain) and availability (e.g.\nin cases of acute intoxication or overdose. TCAs are continuous availability, costs).\ntherefore recommended for consideration in cases y Support the person in making a decision between\nwhere SSRIs are not available for adults with panic antidepressants and psychological interventions (if\ndisorder. available), based on providing relevant information\ny TCAs should be avoided in older adults and in (e.g. possible side-effects, costs). Before prescribing (ssris for gad; ssris as first-line treatment and then\ncitalopram indicated minimal efficacy and high nguy cơ\ntcas as second-line treatment for panic disorder)\nof adverse events. however, individual analyses are\nthat are..."
}